Dr. Chaplin raises questions about the dropout rate and the use of statistical analysis. Of the 330 patients who entered the study, 133 (40.3%) completed the 1-year investigation, whereas 197 (59.7%) discontinued treatment prematurely. The reasons for discontinuation (with percentages of the total group) were as follows: adverse events (N=87, 26.4%), voluntary discontinuation or administrative reasons (N=77, 23.3%), inadequate response (N=15, 4.5%), or intercurrent illness or abnormal laboratory results (N=18, 5.5%). The types of adverse events ranged from rigidity, agitation, and depression to cellulitis, pneumonia, and, in 8.8% of the patients (N=29), death. Given the advanced age of the subjects and the severity of their cognitive impairment, it is not surprising that a substantial proportion of these institutionalized patients experienced adverse events, whether related to the study medication or not. Because of the design of the investigation, our report did not provide good evidence to address causal associations of any of these events with risperidone therapy.